Stay updated with breaking news from Us Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA Also Approves and Closes RECOVER III Post-Approval Study Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella
/PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark...
Through collaborations with Le Bonheur Children's Hospital, the Wisconsin Health Information Organization, and Yale University, UCB seeks to further understand...
Consistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-supported
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of